Hims vs Medvi: DTC Telehealth and a Compounding Clinic

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Comparing a large direct-to-consumer telehealth brand with a compounding-focused wellness clinic is really a question of scale versus specialization. This PlexusDx Education Hub review sets Hims next to Medvi on those terms, then closes on a biological factor that neither the big brand nor the boutique clinic measures. Browse all Peptides & GLP-1 education.

Full head-to-head: PlexusDx vs MEDVi →

Editorial independence: PlexusDx has no commercial relationship with Hims, Medvi, or their parent organizations. This review carries no affiliate links, sponsorship, or referral compensation.

Hims is a broad consumer-health brand that offers GLP-1 therapy among many services, while Medvi Wellness centers on compounded weight-management care. That difference in breadth shapes how each feels to a patient. Below we examine each brand's positioning, the compounded route, cost drivers, and the inherited variable that sits outside both. Details reflect public information as of April 2026.

Hims as a broad consumer-health brand

Hims, part of Hims & Hers Health, runs subscription telehealth across a wide catalog, with GLP-1 weight management as one line. A virtual evaluation leads to a licensed clinician's review and, where appropriate, either an FDA-approved brand GLP-1 or a compounded semaglutide or tirzepatide from a licensed compounding pharmacy. Current details are at Hims's official website.

Medvi as a compounding-focused clinic

Medvi Wellness positions itself around telehealth paired with compounded-pharmacy fulfillment, a narrower focus than a broad consumer brand. Its medication options, membership terms, and totals change over time, so the authoritative source is Medvi's official website at the moment you evaluate it.

Scale versus specialization: what it changes

Breadth and focus each carry tradeoffs. A large brand may offer polished onboarding, brand recognition, and a wide catalog, while a specialized clinic may concentrate its attention on the weight-management category. Neither is inherently better for a given patient; the right fit depends on whether you value a one-stop platform or a service built narrowly around compounded GLP-1 care. The clinical fundamentals matter more than the size of the catalog.

The compounded route both can use

Both brands can route prescriptions to licensed 503A compounding pharmacies, which prepare a medication for an individual patient against a valid prescription. The active molecule in a compounded semaglutide or tirzepatide belongs to the same pharmacologic family as the branded product, though preparation and presentation can differ. Whether you go with the big brand or the boutique clinic, understanding the dispensing route tells you more than the marketing does.

The pharmacology and its evidence

Scale does not change chemistry. GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, plus the dual GIP/GLP-1 agonist tirzepatide, act on appetite, satiety, and gastric emptying. The class is well studied: STEP for semaglutide in weight management (New England Journal of Medicine, 2021), SURMOUNT for tirzepatide (NEJM, 2022), and SURMOUNT-OSA for tirzepatide in obstructive sleep apnea (NEJM, 2024). Doses and endpoints vary, and averages never guarantee an individual result.

What shapes the cost

Across GLP-1 telehealth as of April 2026, monthly totals commonly land in a broad band of roughly $200 to $700 or more, driven by the compound, subscription term, and dispensing fees. A broad brand and a specialized clinic may assemble those costs differently. Because figures move, confirm each brand's live pricing on its own page before committing rather than relying on a number that may be stale.

The variable neither model captures

Whether the service is large or boutique, it does not read the inherited biology a GLP-1 acts on. A variant in FTO, the fat-mass and obesity-associated gene, together with GLP1R (the receptor these compounds target), MC4R (central to satiety), and TCF7L2 (linked to glucose handling), maps your baseline metabolic terrain. These pathway-level markers do not predict how a specific compound will perform, but they describe the ground any protocol operates on.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Before a protocol, the Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, including FTO, MC4R, and TCF7L2. Test before you invest.

Not affiliated: PlexusDx has no relationship with Hims or Medvi and reviewed both independently.

Related reading on PlexusDx: GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone, What Is GLP 1.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hims or Medvi and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx approach in the Weight Management Protocols, or start with the Precision Peptide Genetic Test.

Frequently Asked Questions

Is a specialized clinic like Medvi better than a broad brand like Hims?

Neither is objectively better. A broad brand may offer a wider catalog and polished onboarding, while a specialized clinic concentrates on weight management. The right fit depends on whether you prefer a one-stop platform or a narrowly focused service. Compare clinical oversight and dispensing details on each brand's own site.

Do both Hims and Medvi use compounded medication?

Both can route prescriptions to licensed 503A compounding pharmacies, and Hims may also dispense FDA-approved branded products depending on its program. Which route applies affects format and cost, so confirm on each brand's own site whether your specific medication would be compounded or branded before ordering.

Does the Precision Peptide Genetic Test depend on brand size?

No. The test is independent of any telehealth brand, large or boutique, and does not predict drug response. It maps pathway-level variants such as FTO and MC4R, and TCF7L2 that describe your baseline metabolic biology, offering context that applies regardless of which service you choose.

How does PlexusDx compare with Hims and Medvi?

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols and adds upstream genetic context via the Precision Peptide Genetic Test, mapping FTO, MC4R. That pathway-level insight is the layer that neither a broad brand like Hims nor a clinic like Medvi provides.

More in the Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.